Clinical Trial Update: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan [Phase 2]

View source ↗

Summary

A Phase 2 study in Japan evaluating pexidartinib for tenosynovial giant cell tumor has posted results (as of 2025-03-03); the trial status is active_not_recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tenosynovial Giant Cell Tumor

Drugs mentioned

• Pexidartinib (pexidartinib)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Tenosynovial Giant Cell Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-03